Evaluation of a Novel Quantum-Inspired Intervention (QII) for Children With Autism Spectrum Disorder: A Global Confirmatory Study

STUDY RATIONALE AND OBJECTIVES Autism Spectrum Disorder (ASD) involves complex neurodevelopmental dynamics characterized by challenges in emotional regulation and adaptive functioning. Existing clinical paradigms primarily rely on pharmaceuticals for secondary symptom control or behavioral methods aimed at external behavioral modification, while interventions targeting core functional shifts remain limited.

While fully elucidating the fundamental mechanisms will require extended scientific timelines, the urgent needs of individuals and families make confirming tangible, real-world functional efficacy the paramount priority. This global multicenter confirmatory study is designed to evaluate the clinical efficacy and safety of Quantum-Inspired Intervention (QII), a novel non-invasive neurodevelopmental protocol, in children diagnosed with Autism Spectrum Disorder (ASD).

CONCEPTUAL FRAMEWORK AND OPERATIONAL WORKFLOW Grounded in a quantum-inspired conceptual framework aimed at addressing foundational adaptive processing rather than superficial behavior management, QII integrates AI-enabled, fine-grained characterization of each child's needs with a proprietary quantum-inspired intervention protocol delivered by trained practitioners.

All randomized participants, in both the experimental and waitlist control arms, complete the identical workflow described below; the QII protocol itself is delivered only to the experimental arm during the study period, and to the waitlist control arm following completion of the primary analysis.

The procedural workflow and operational division of responsibilities across the trial follow a standardized five-stage cycle:

• Caregiver Intake and Structured Data Collection: Participating caregivers access a secure, web-based digital portal to submit multidimensional behavioral and developmental inputs regarding their child. Caregivers complete structured questionnaires covering functional communication, social responsiveness, and emotional stability, alongside qualitative observations via text, voice, or video logs documenting daily communication attempts, emotional regulation difficulties, sleep routines, and behavioral patterns.
• AI-Enabled Processing and High-Granularity Synthesis: The platform's AI pipeline operates in an administrative, analytical, and coordination support capacity. It transcribes audio/video submissions, indexes observational records, and performs fine-grained characterization across expansive behavioral domains. This automated pipeline synthesizes the complex developmental inputs into structured data profiles to accelerate clinical review while maintaining strict procedural consistency.
• Pattern Identification, Developmental Report, and Family Alignment: Trained practitioners review the synthesized data profiles to identify one to two primary focal dysregulation targets or dominant developmental priorities (e.g., expressive communication initiation or emotional volatility). The practitioner generates an individualized Developmental Report delineating these target intervention points and shares it directly with the family. The caregiver reviews, confirms, and formally signs off on the alignment plan, ensuring mutual agreement on the targeted developmental objectives prior to protocol initiation.
• Application of Standardized QII Protocol: Upon formal alignment, trained practitioners deliver the proprietary quantum-inspired intervention (QII) protocol. The intervention is conducted entirely remotely without requiring the family or child to travel to physical clinical sites. It imposes no added physical or labor-intensive training demands on the family; participating households simply maintain their normal daily living routines and lifestyle patterns. The protocol operates as a standardized, non-invasive, and non-contact regulatory methodology designed to stimulate foundational adaptive processing and functional improvement.
• Continuous Monitoring and Standardized Post-Intervention Reassessment: Throughout the 3-month intervention window, caregivers may voluntarily submit periodic observational notes or behavioral reflections through the portal. At the conclusion of month 3, a formal reassessment is conducted: caregivers complete the exact same structured intake questionnaire and data collection battery administered at baseline. Platform-generated profiles are used for intervention planning and process documentation only; formal efficacy endpoints are evaluated independently by blinded assessors, as described in Section 4.

STUDY TIMELINE AND CLINICAL PHASING

The overall clinical trial is conducted over a comprehensive 12-month operational timeline across participating sites, encompassing multicenter patient recruitment, standardized intervention delivery, blinded endpoint assessment, and statistical data lock:

• Screening and Enrollment (Months 1-2): Multicenter participant recruitment, diagnostic verification of ASD, informed consent acquisition, and eligibility confirmation.
• Preparation Phase (Month 3): Caregiver intake and structured data collection, AI-enabled fine-grained characterization, preparation of individualized Developmental Reports, and formal caregiver alignment and sign-off.
• Baseline Assessment and Randomization (Month 4): Blinded baseline endpoint assessments by independent assessors, followed by randomization to the experimental or waitlist control arm.
• Active Intervention Phase (Months 5-7): Standardized multi-cycle delivery of the proprietary QII protocol to the experimental arm over a 3-month intervention period, while the waitlist control arm continues the identical procedural workflow without receiving QII. Caregivers may report adverse events or safety concerns at any time through the study portal and may request to discontinue the intervention at any time.
• Data Verification and Consolidation (Months 8-9): Finalization of multicenter data collection, data cleaning, and independent monitoring verification.
• Statistical Analysis and DMC Review (Months 10-11): Primary statistical analysis and independent Data Monitoring Committee review of safety and data integrity.
• Results Reporting (Month 12): Trial closeout and regulatory registry reporting.
• Waitlist Control Extension Phase (from Month 12): Following completion of the primary analysis, participants in the waitlist control arm will be offered the QII protocol, provided that no safety concerns have been identified by the DMC. Outcomes from this phase will be reported as exploratory.

OUTCOME MEASURES AND ENDPOINT SPECIFICATIONS

The trial employs validated, objective clinical instruments to evaluate tangible gains in adaptive communication, emotional self-regulation, and overall clinical response:

Primary Outcome

Title：Clinical Global Impression-Improvement (CGI-I) Score for the Primary Intervention Target Description：CGI-I rated by a blinded independent clinician on a 7-point scale (1 = very much improved; 7 = very much worse), assessing improvement relative to baseline in the autism-related symptom or functional difficulty identified as the primary intervention target at baseline.

Time Frame：End of the 3-month intervention period

Secondary Outcome

Title：Change from Baseline in Aberrant Behavior Checklist-Irritability Subscale (ABC-I) Score Description：ABC-I subscale (15 items; score range 0-45; higher scores indicate greater irritability), completed by caregivers under the administration of a blinded assessor.

Time Frame：Baseline and end of the 3-month intervention period

• Independent Blinded Outcome Assessment: To ensure objectivity, all efficacy endpoints are assessed by independent, licensed clinicians at participating partner hospitals who are external to the sponsor and the intervention team. Outcome assessors are blinded to participants' group allocation and have no involvement in intervention delivery, Developmental Report preparation, or practitioner-family communication. Assessments are conducted at baseline and at the conclusion of the 3 months intervention period. The CGI-I is rated by the blinded assessor, and the ABC-I is completed by caregivers under the assessor's administration. Caregivers are instructed not to disclose intervention-related information to assessors.
• Safety Endpoints: Incidence, severity, and potential causality of adverse events (AEs), reported by caregivers at any time through the study portal and systematically recorded at the mid-point review and end-of-intervention assessment. Caregivers may request to discontinue the intervention at any time without affecting their child's access to other care.